Prosigna®

Breast Cancer Assay

THE PROSIGNA BREAST CANCER TEST

What is it and what does it mean for me?

How can I confidently choose the best treatment for my breast cancer?

Post-menopausal women with early-stage hormone receptor-positive (HR+, estrogen receptor)

veracyte®

Prosigna®

Breast Cancer Assay

The Prosigna test provides important and comprehensive information that helps breast cancer patients and their doctors choose the best treatment.

What happens after I'm diagnosed with breast cancer?

Breast cancer is the most common cancer in women, and numbers have increased in the last 5 years. In 2020, 2.3 million women worldwide were diagnosed, which represents one in 15 women who will develop breast cancer in their lifetime.[1]

Your treatment choice is an essential decision defining your ultimate outcome.

A breast cancer diagnosis doesn't have to shorten your life anymore but it needs to be treated.

Surgical tumor removal is a must but the choice of chemotherapy, hormone therapy, radiation or other treatment depends on multiple factors and is very individualized.

The more you and your doctor know about your tumor, the more precise and effective the treatment can be.



Screening or symptomatic presentation

- Breast imaging
- Medical history
- Physical examination
- Biopsies

Confirmed diagnosis

Testing on tumor sample

Prosigna test result

- Tissue stays in the local laboratory
- Analysis is performed by hospital's own staff
- Your results are available in a few days

Discussion with your doctor about treatment options

- Local/regional treatment (surgery and radiotherapy directed where your cancer started)
- Systemic therapy (medical treatment directed to cancer cells that may have spread throughout your body)

Knowing how likely it is that your cancer will come back can help you and your doctor choose the best treatment.

In recent years, new diagnostic tests have been developed to help health care professionals choose the most efficient treatment for their patients.

What is the Prosigna test?

Prosigna is a genomic test which identifies the likelihood your cancer may return over the next 10 years. This is known as distant recurrence. By assessing this risk, Prosigna can provide a more complete understanding of your breast cancer.

Prosigna utilizes the PAM50 gene signature to find the genomic fingerprint of your tumor, also referred to as intrinsic subtype. Using an automated process, your subtype is combined with other factors including tumor size and number of involved lymph nodes to help determine your risk of distant recurrence. Looking ahead 10 years may help you and your physician make more confident choices today.

Am I eligible?

Prosigna is indicated for use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II) or node-positive (Stage II) early-stage breast cancer.

See the Prosigna Package Insert for full intended use.

The Prosigna test was developed to help your oncologist assess which treatment is the most suitable for you.

How does the Prosigna test work?

The Prosigna test provides a Risk of Recurrence (ROR) score. This number estimates the likelihood that your cancer will return in some other parts of your body if you only receive endocrine (hormone) therapy. This is based on:

- The size of your tumor
- The intrinsic molecular subtype
- How quickly your disease is growing
- And the nodal status (whether the disease has entered the lymph nodes)

The Prosigna test has been validated with 2400 postmenopausal women before being approved by regulatory authorities as providing accurate information.

The Prosigna test gives you and your doctor more information.

Subtype-based analysis

Not all breast cancers are the same. They can be classified by stage, nodal involvement and other factors. Based on this information your doctor is able to tailor your treatment.

The Prosigna report provides an accurate assessment of your risk of recurrence

The Prosigna report is delivered directly to your oncologist in a few days and includes important results:

- **Your Prosigna Score**, including ROR subcomponents for predominant intrinsic molecular subtype and proliferation score*, which is a numerical value on a 0-to-100 scale. A lower number indicates your cancer is less likely to return. A higher number indicates there is a higher chance your cancer may return.
- **Your Risk Category**, (Low, Intermediate, or High) indicates how likely your cancer will return within 10 years. In combination with other aspects, such as your age, other health issues, the size and grade of your tumour, and hormone receptors present in your breast cancer, your risk category will help you and your oncologist make the best treatment decision for you.

These results will help your doctor to recommend the best possible treatment options so you can choose with confidence.

The Prosigna report

The Prosigna patient report is customized to contain test results and information specific to each patient.

Prosigna test patient profile

Mrs. B.M., 68

Surgery: Breast conserving surgery (BCS) and sentinel lymph node biopsy (SLNB)

Pathology: Invasive ductal cancer (IDC) grade III 15mm

✓	Female
✓	Post-menopausal
✓	Hormone receptor-positive
✓	Surgery + Local/regional treatment with surgery and radiation
✓	Lymph Node Negative + Stage I or II OR Lymph Node Positive (1-3) Stage II

The Prosigna test provides more comprehensive information about your cancer, and the risk of it returning in other parts of your body. It enables your doctor to define a personalized and precise treatment plan.

Thousands of patients around the world have already chosen to use the Prosigna test. This test has allowed them to adapt their treatment, choosing with their doctor what is right for them.

When and how is my Prosigna test performed?

After surgery, the Prosigna test does not require any additional steps on your part and is performed in local laboratories, allowing a quick result in a few days.

Prosigna request	Tissue sample	Tissue review	Prosigna analysis	Prosigna report
Oncologist (ordering provider) requests Prosigna Breast Cancer Assay	Samples from your tumor are sent to a local laboratory	Pathologist confirms that there is enough tissue to do the Prosigna test	Sample is prepared and the Prosigna test is performed	Prosigna test results are provided to your doctor



Please ask your doctor if you would like to get any further details about the test, or visit our website:

www.prosigna.com/en/patients

Prosigna®

Breast Cancer Assay

Veracyte is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. We aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally.

For more information about Prosigna, call 1.888.923.4762
Prosigna.com

1. Breast cancer - WHO | World Health Organization
*The Intrinsic Molecular Subtype (Luminal A, Luminal B, HER2-enriched or Basal-like) and proliferation score are reported as constituent components of the ROR. Their correspondence with histopathological subtyping is not established. The intrinsic molecular subtype and proliferation score are not intended to be used for treatment decisions.

MKTG_PRSGN_BRO_072123_011_03

veracyte®